ClinicalTrials.gg
TerminatedNCT04811092HYPERIONUpdated Jun 8, 2026Results posted

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

A Phase 3 interventional study of Sotatercept and Placebo in Pulmonary Arterial Hypertension, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Terminated at 152 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
321
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.

Enrollment
3rd of 18
321 · median 44
Started
2022
the only one that year
Phase 3
5 of 18
none open now
Registered
4th of 18
by date
Lead sponsor
5 of 18
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 3rd largest by enrollment, is the only one that started in 2022, is one of 5 in phase 3, and was the 4th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About sotatercept

sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sotatercept in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in participants who are newly diagnosed with PAH and are at intermediate or high-risk of disease progression.

Read the detailed description

This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate sotatercept when added to background PAH therapy in newly diagnosed intermediate- or high risk PAH participants.

Participants enrolled in the study will have a diagnosis within 12 months of study screening of symptomatic PAH (World Health Organization [WHO] Group 1, classified as functional class [FC] II or III) and presentation of idiopathic or heritable PAH, PAH associated with connective tissue diseases (CTD), drug- or toxin- induced PAH, post shunt correction PAH, or PAH presenting at least 1 year following the correction of congenital heart defects.

As of Amendment 11, this study will be closed so that all eligible participants can receive sotatercept either on the MK-7962-004 extension study (SOTERIA, NCT04796337) or by commercial access, if available. All eligible participants will complete the end of treatment visit before enrollment in the extension study or initiation of commercial product. Participants not enrolling into the extension study or initiating commercial product will complete the end of study visit.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary
  • Hypertension
  • Sotatercept
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion criteria include but are not limited to:

  • Documented diagnostic right heart catheterization (RHC) within 12 months of screening documenting a minimum pulmonary vascular resistance (PVR) of ≥ 4 Wood units and pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg, with the diagnosis of WHO PAH Group 1 in any of the following subtypes:

    • Idiopathic PAH
    • Heritable PAH
    • Drug/toxin-induced PAH
    • PAH associated with connective tissue disease
    • PAH associated with simple, congenital systemic to pulmonary shunts at least 1 year following repair
  • Symptomatic PAH classified as World Health Organization (WHO) Functional Class (FC) II or III
  • Either Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) Lite 2 Risk Score ≥ 6 or Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) 2.0 risk score ≥2 (intermediate to-low-risk or above)
  • Diagnosis of PAH within 12 months of screening and on stable doses of a double or triple combination of background PAH therapies and diuretics (if any) for at least 90 days prior to screening
  • Six-minute walk distance ≥ 150 m repeated twice at screening at least 4 hours apart, but no longer than 1 week apart, and both values are within 15% of each other (calculated from the highest value)
  • Females of must meet the following criteria:

    • Have 2 negative urine or serum pregnancy tests as verified by the investigator prior to starting study drug administration; she must agree to ongoing urine or serum pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug
    • If sexually active with a male partner, have used highly effective without interruption, for at least 28 days prior to starting the product AND agreed to use the same highly effective contraception in combination with a barrier method during the study (including dose interruptions) and for 16 weeks (112 days) after discontinuation of study treatment
    • Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment
  • Male participants must meet the following criteria:

    • Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy
    • Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment

Exclusion Criteria:

Exclusion Criteria include but are not limited to:

  • Diagnosis of pulmonary hypertension (PH) WHO Groups 2, 3, 4, or 5
  • Diagnosis of the following PAH Group 1 subtypes: (HIV)-associated PAH and PAH associated with portal hypertension, schistosomiasis-associated PAH, pulmonary veno occlusive disease, and pulmonary capillary hemangiomatosis
  • at screening above gender-specific (ULN), per local laboratory test
  • Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) > 180 mmHg or sitting diastolic BP > 110 mmHg during the Screening Visit after a period of rest
  • Baseline systolic BP \< 90 mmHg at screening
  • Pregnant or breastfeeding women
  • Any of the following clinical laboratory values at the Screening Visit:

    • Estimated \< 30 mL/min/1.73 m\^2 (as defined by The Modification of Diet in Renal Disease [MDRD] equation)
    • Serum , aspartate aminotransferase, and total levels > 3 × ULN
    • count \< 50,000/mm\^3 (\< 50.0 × 10\^9 /L)
  • Currently enrolled in or have completed any other investigational product study within 30 days for small molecule drugs or within 5 half-lives for investigational biologics prior to the date of documented
  • Known allergic reaction to sotatercept (ACE-011), its , or luspatercept
  • History of pneumonectomy
  • Pulmonary function test values of forced vital capacity \< 60% predicted within 1 year prior to the Screening Visit
  • Stopped receiving any PH chronic general supportive therapy (e.g., diuretics, oxygen, anticoagulants, and digoxin) within 60 days prior to the Screening Visit
  • Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to the Screening Visit or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible)
  • Untreated more than mild obstructive sleep apnea
  • History of known pericardial constriction
  • History of restrictive or congestive cardiomyopathy
  • History of atrial septostomy within 180 days prior to the Screening Visit
  • with Fridericia's interval > 500 ms during the Screening Period
  • Personal or family history of long QT syndrome or sudden cardiac death
  • \< 50% on historical echocardiogram (ECHO) within 1 year prior to the Screening Visit
  • Any current or prior history of symptomatic coronary disease (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) in the past 6 months prior to the Screening Visit
  • Cerebrovascular accident within 3 months prior to the Screening Visit
  • Acutely decompensated heart failure within 30 days prior to the Screening Visit, as per investigator assessment
  • Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease
  • Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, and vasopressin) within 30 days prior to the Screening Visit
  • Has an active with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or prostate cancer that is not currently or expected, during the study, to be treated with radiation therapy, chemotherapy, and/or surgical intervention, or hormonal treatment
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
321 participants (actual)

Study arms

  • Experimental
    Sotatercept plus background PAH therapy

    Participants received sotatercept at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, subcutaneously (SC) every 21 days plus background PAH therapy.

    Drug: Sotatercept

  • Placebo comparator
    Placebo plus background therapy

    Participants received placebo SC every 21 days plus background PAH therapy.

    Other: Placebo

Interventions

  • SC injection

    Also known as: MK-7962, ACE-011

  • OtherPlacebo

    Placebo-matched SC injection

06

What researchers measure

Primary outcomes

  1. Median Time to Clinical Worsening

    Time to clinical worsening (TTCW) is defined as time from randomization to the first confirmed morbidity event or death. Clinical worsening events are defined as all-cause death, non-planned PAH-related hospitalization of ≥ 24 hours in duration, atrial septostomy, lung transplant, and/or deterioration in performance in 6-minute walk test from baseline combined with one of the following conditions: worsening of WHO FC from baseline, signs/symptoms of increased right heart failure, addition of a background PAH therapy or change in the background PAH therapy delivery route to parenteral. All events were adjudicated by a blinded, independent committee of clinical experts. The median TTCW is presented.

    Time frame: Up to ~35 months

Secondary outcomes

  1. Percentage of Participants Achieving the Multicomponent Improvement Endpoint of 6-Minute Walk Distance (6MWD), N-terminal Prohormone B-type Natriuretic Peptide (NT-ProBNP) WHO FC

    The multicomponent improvement outcome measure is determined by the percentage of participants achieving all of the following at Week 24 relative to baseline: * Improvement in 6MWD (increase ≥30 m) * Improvement or maintenance/achievement of NT-proBNP (decrease in NT-proBNP ≥30%) or maintenance/achievement of NT-proBNP level \<300 ng/L * Improvement in WHO FC or maintenance of WHO FC II (indicated by maintaining the same WHO FC or a lower WHO FC by Week 24 relative to baseline) The percentage of participants achieving the multicomponent improvement endpoint is presented.

    Time frame: Baseline and Week 24

  2. Percentage of Participants Who Maintained or Achieved a Low Registry to Evaluate Early and Long Term PAH Disease Management (REVEAL) Lite 2 Risk Score

    REVEAL Lite 2.0 risk scoring is used to guide PAH treatment decisions. Total score uses 6 variables with each assessed based on contribution to mortality risk. Variables and sub-score ranges: estimated glomerular filtration rate \[eGFR\] (0, +1), WHO FC (-1, 0, +1, +2), SBP (0, +1), heart rate (0, +1), 6MWD (-2, -1, 0, +1), and NT-proBNP (-2, 0, +2). Sub-scores are added to a base score of +6 and a total score of 1 to 14 is obtained (≤5=low risk; 6,7=intermediate risk; ≥8=high risk). A higher score = higher risk. Per SAP, participants who did not have a REVEAL risk score at Week 24 were considered as non-responders and multiple imputation was not conducted for this endpoint. Comparisons between this analysis reporting non-imputed data should not be made to other REVEAL analyses which included imputation of missing Week 24 data. The percentage of participants who maintained or achieved a low REVEAL Lite 2.0 score at Week 24 is reported.

    Time frame: Baseline and Week 24

  3. Percentage of Participants Who Maintained or Achieved a Low Simplified French Risk Score

    The simplified French Risk Score uses WHO FC, 6MWD, and NT-proBNP to determine the total risk score. A low risk score can be defined as attaining or maintaining all three low-risk criteria: WHO FC I or II, 6MWD \> 440m, and NT-proBNP \< 300 ng/L. The percentage of participants who maintained or achieved a low risk score at Week 24 versus baseline using the simplified French Risk score calculator is presented.

    Time frame: Baseline and Week 24

  4. Median Change From Baseline in NT-proBNP Levels at Week 24

    NT-proBNP is a circulating biomarker that reflects myocardial stretch and is an established biomarker used to determine the ventricular dysfunction in participants with PAH. NT-proBNP was measured at Day 1 (baseline) and at Week 24. The median change from baseline in NT-proBNP at Week 24 is presented.

    Time frame: Baseline and Week 24

  5. Percentage of Participants Who Improved in WHO FC or Maintained WHO FC II at 24 Weeks From Baseline

    The severity of an individual's PAH symptoms was graded using the WHO FC system. WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO FC is classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC. The percentage of participants who improved in WHO FC or maintained WHO FC II at 24 Weeks from Baseline is presented.

    Time frame: Baseline and Week 24

  6. Median Change From Baseline in Six-Minute Walk Distance (6MWD)

    The 6-minute walk distance (6MWD) was measured using the 6-Minute Walk Test (6MWT). The 6MWT measures the distance covered in 6 minutes and is intended to measure changes in functional exercise capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicated improvement in functional exercise capacity. Median change from baseline in 6MWD at Week 24 is reported.

    Time frame: Baseline and Week 24

  7. Overall Survival (OS)

    Overall survival is defined as the time from randomization to date of death due to any cause. OS is presented.

    Time frame: Up to ~35 Months

  8. Mean Change From Baseline in the Physical Impacts Domain Score of Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT)®

    The PAH SYMPACT is a 23-item questionnaire to measure pulmonary arterial hypertension (PAH)-related symptoms and impact of PAH on daily life. The physical impact domain consists of walking slowly on a flat surface, walking quickly on a flat surface, walking uphill, carrying things, doing light indoor household chores, washing, or dressing oneself, and needing help from others. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (not difficult at all) to 4 (extremely difficult). A domain score was calculated by summing the individual responses for each item and dividing by the number of impact items (range: 0=no physical impact to 4=severe physical impact). A higher score indicated more severe physical impact. Mean change from baseline in responses in physical symptoms of the PAH-SYMPACT questionnaire at Week 24 is reported.

    Time frame: Baseline and Week 24

  9. Mean Change From Baseline in the Cardiopulmonary Symptoms Domain Score of PAH-SYMPACT®

    The PAH SYMPACT is a 23-item questionnaire to measure PAH-related symptoms and impact of PAH on daily life. The cardiopulmonary symptoms consist of shortness of breath, fatigue, lack of energy, swelling in the ankles or legs, swelling in the stomach area, and cough. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (no symptom at all) to 4 (very severe symptoms). The mean individual symptom item score was determined for each of the 6 items and a domain score was calculated by summing the mean individual symptom item scores and dividing by the number of items (range: 0=no cardiopulmonary symptoms to 4=severe cardiopulmonary symptoms). A higher score indicated more severe symptoms experienced. Mean change from baseline in cardiopulmonary symptoms of the PAH-SYMPACT questionnaire at Week 24 is reported.

    Time frame: Baseline and Week 24

  10. Mean Change From Baseline in the Cognitive/Emotional Impacts Domain Score of PAH-SYMPACT®

    The PAH SYMPACT is a 23-item questionnaire to measure PAH-related symptoms and impact of PAH on daily life. The Cognitive/Emotional Impact domain consists of thinking clearly, feeling sad, feeling worried, and feeling frustrated. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (not difficult at all) to 4 (extremely difficult). A domain score was calculated by summing the individual responses for each item and dividing by the number of impact items (range: 0=no cognitive/emotional impact to 4=severe cognitive/emotional impact). A higher score indicated more severe cognitive/emotional impact. Mean change from baseline in responses in the Cognitive/Emotional Impacts Domain Score of the PAH-SYMPACT questionnaire at Week 24 is reported.

    Time frame: Baseline and Week 24

  11. Percentage of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical investigation participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experienced an AE are presented.

    Time frame: Up to ~35 Months

  12. Percentage of Participants Who Discontinued Study Treatment Due to AEs

    An AE is any untoward medical occurrence in a clinical investigation participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study treatment due to an AE are presented.

    Time frame: Up to ~35 months

  13. Number of Participants Who Had Anti-drug Antibodies (ADAs) to Sotatercept

    Blood samples collected at designated timepoints were used to determine the ADA response to sotatercept. The number of participants who had ADAs to sotatercept over time is presented.

    Time frame: Up to ~35 Months

07

Results

Posted Apr 27, 2026
Limitations and caveats
Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.

Participant flow

Participant flow — Overall Study
MilestoneSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Started161160
Treated160160
Completed143149
Not completed1811
Withdrew: Adverse event50
Withdrew: Death45
Withdrew: Randomized by mistake10
Withdrew: Protocol non-compliance12
Withdrew: Withdrawal by subject74

Outcome measures

SecondaryPercentage of Participants Achieving the Multicomponent Improvement Endpoint of 6-Minute Walk Distance (6MWD), N-terminal Prohormone B-type Natriuretic Peptide (NT-ProBNP) WHO FC

The multicomponent improvement outcome measure is determined by the percentage of participants achieving all of the following at Week 24 relative to baseline: * Improvement in 6MWD (increase ≥30 m) * Improvement or maintenance/achievement of NT-proBNP (decrease in NT-proBNP ≥30%) or maintenance/achievement of NT-proBNP level \<300 ng/L * Improvement in WHO FC or maintenance of WHO FC II (indicated by maintaining the same WHO FC or a lower WHO FC by Week 24 relative to baseline) The percentage of participants achieving the multicomponent improvement endpoint is presented.

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving the Multicomponent Improvement Endpoint of 6-Minute Walk Distance (6MWD), N-terminal Prohormone B-type Natriuretic Peptide (NT-ProBNP) WHO FC
Percentage of participantsSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Percentage of Participants Achieving the Multicomponent Improvement Endpoint of 6-Minute Walk Distance (6MWD), N-terminal Prohormone B-type Natriuretic Peptide (NT-ProBNP) WHO FC29.414.6
Statistical analysis
  • Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) Therapy vs Placebo Plus Background PAH Therapy · Cochran-Mantel-Haenszel · p = 0.003 · Percentage point difference: 14.5 · 95% CI 5.1 to 23.9Based on the Miettinen and Nurminen method stratified by randomization stratification factors.
PrimaryMedian Time to Clinical Worsening

Time to clinical worsening (TTCW) is defined as time from randomization to the first confirmed morbidity event or death. Clinical worsening events are defined as all-cause death, non-planned PAH-related hospitalization of ≥ 24 hours in duration, atrial septostomy, lung transplant, and/or deterioration in performance in 6-minute walk test from baseline combined with one of the following conditions: worsening of WHO FC from baseline, signs/symptoms of increased right heart failure, addition of a background PAH therapy or change in the background PAH therapy delivery route to parenteral. All events were adjudicated by a blinded, independent committee of clinical experts. The median TTCW is presented.

Time frame:
Up to ~35 months
Reported as:
Median · Months
Median Time to Clinical Worsening
MonthsSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Median Time to Clinical WorseningNA (NA to NA)23.0 (17.3 to NA)
Statistical analysis
  • Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) Therapy vs Placebo Plus Background PAH Therapy · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.24 · 95% CI 0.14 to 0.41Based on Cox Regression Model with Efron's Method of tie handling with treatment as a covariate stratified by the randomization stratification factors.
SecondaryPercentage of Participants Who Maintained or Achieved a Low Registry to Evaluate Early and Long Term PAH Disease Management (REVEAL) Lite 2 Risk Score

REVEAL Lite 2.0 risk scoring is used to guide PAH treatment decisions. Total score uses 6 variables with each assessed based on contribution to mortality risk. Variables and sub-score ranges: estimated glomerular filtration rate \[eGFR\] (0, +1), WHO FC (-1, 0, +1, +2), SBP (0, +1), heart rate (0, +1), 6MWD (-2, -1, 0, +1), and NT-proBNP (-2, 0, +2). Sub-scores are added to a base score of +6 and a total score of 1 to 14 is obtained (≤5=low risk; 6,7=intermediate risk; ≥8=high risk). A higher score = higher risk. Per SAP, participants who did not have a REVEAL risk score at Week 24 were considered as non-responders and multiple imputation was not conducted for this endpoint. Comparisons between this analysis reporting non-imputed data should not be made to other REVEAL analyses which included imputation of missing Week 24 data. The percentage of participants who maintained or achieved a low REVEAL Lite 2.0 score at Week 24 is reported.

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Maintained or Achieved a Low Registry to Evaluate Early and Long Term PAH Disease Management (REVEAL) Lite 2 Risk Score
Percentage of ParticipantsSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Percentage of Participants Who Maintained or Achieved a Low Registry to Evaluate Early and Long Term PAH Disease Management (REVEAL) Lite 2 Risk Score60.147.9
Statistical analysis
  • Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) Therapy vs Placebo Plus Background PAH Therapy · Cochran-Mantel-Haenszel · p = 0.036 · Percentage point difference: 12.3 · 95% CI 0.8 to 23.5Based on Miettinen and Nurminen method stratified by the randomization stratification factors.
SecondaryPercentage of Participants Who Maintained or Achieved a Low Simplified French Risk Score

The simplified French Risk Score uses WHO FC, 6MWD, and NT-proBNP to determine the total risk score. A low risk score can be defined as attaining or maintaining all three low-risk criteria: WHO FC I or II, 6MWD \> 440m, and NT-proBNP \< 300 ng/L. The percentage of participants who maintained or achieved a low risk score at Week 24 versus baseline using the simplified French Risk score calculator is presented.

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Maintained or Achieved a Low Simplified French Risk Score
Percentage of ParticipantsSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Percentage of Participants Who Maintained or Achieved a Low Simplified French Risk Score18.213.2
Statistical analysis
  • Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) Therapy vs Placebo Plus Background PAH Therapy · Cochran-Mantel-Haenszel · p = 0.246 · Percentage point difference: 5.0 · 95% CI -3.5 to 13.6Based on Miettinen and Nurminen method stratified by the randomization stratification factors.
SecondaryMedian Change From Baseline in NT-proBNP Levels at Week 24

NT-proBNP is a circulating biomarker that reflects myocardial stretch and is an established biomarker used to determine the ventricular dysfunction in participants with PAH. NT-proBNP was measured at Day 1 (baseline) and at Week 24. The median change from baseline in NT-proBNP at Week 24 is presented.

Time frame:
Baseline and Week 24
Reported as:
Median · pg/mL
Median Change From Baseline in NT-proBNP Levels at Week 24
pg/mLSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Median Change From Baseline in NT-proBNP Levels at Week 24-199.3 (-211.0 to -188.0)-10.3 (-17.5 to -6.5)
Statistical analysis
  • Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) Therapy vs Placebo Plus Background PAH Therapy · Wilcoxon (Mann-Whitney) · p = 0.001 · Hodges-lehmann location shift: -308.60 · 95% CI -434.84 to -182.37Hodges-Lehmann location shift estimate with 95% CI used aligned rank stratified Wilcoxon test stratified by randomization stratification factors.
SecondaryPercentage of Participants Who Improved in WHO FC or Maintained WHO FC II at 24 Weeks From Baseline

The severity of an individual's PAH symptoms was graded using the WHO FC system. WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO FC is classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC. The percentage of participants who improved in WHO FC or maintained WHO FC II at 24 Weeks from Baseline is presented.

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Improved in WHO FC or Maintained WHO FC II at 24 Weeks From Baseline
Percentage of ParticipantsSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Percentage of Participants Who Improved in WHO FC or Maintained WHO FC II at 24 Weeks From Baseline55.238.9
Statistical analysis
  • Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) Therapy vs Placebo Plus Background PAH Therapy · Cochran-Mantel-Haenszel · p = 0.005 · Percentage point difference: 15.6 · 95% CI 4.7 to 26.3Based on Miettinen and Nurminen method stratified by the randomization factors.
SecondaryMedian Change From Baseline in Six-Minute Walk Distance (6MWD)

The 6-minute walk distance (6MWD) was measured using the 6-Minute Walk Test (6MWT). The 6MWT measures the distance covered in 6 minutes and is intended to measure changes in functional exercise capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicated improvement in functional exercise capacity. Median change from baseline in 6MWD at Week 24 is reported.

Time frame:
Baseline and Week 24
Reported as:
Median · Meters
Median Change From Baseline in Six-Minute Walk Distance (6MWD)
MetersSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Median Change From Baseline in Six-Minute Walk Distance (6MWD)29.1 (28.0 to 32.5)16.1 (14.3 to 19.6)
Statistical analysis
  • Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) Therapy vs Placebo Plus Background PAH Therapy · Wilcoxon (Mann-Whitney) · p = 0.013 · Hodges-lehmann location shift: 21.40 · 95% CI 4.65 to 38.24Aligned Rank Stratified Wilcoxen test using stratification factors from randomization stratification.
SecondaryOverall Survival (OS)

Overall survival is defined as the time from randomization to date of death due to any cause. OS is presented.

Time frame:
Up to ~35 Months
Reported as:
Median · Months
Overall Survival (OS)
MonthsSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) Therapy vs Placebo Plus Background PAH Therapy · Wilcoxon (Mann-Whitney) · p = 0.453 · Hazard ratio (hr): 0.94 · 95% CI 0.31 to 2.81Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by the randomization stratification factors.
SecondaryMean Change From Baseline in the Physical Impacts Domain Score of Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT)®

The PAH SYMPACT is a 23-item questionnaire to measure pulmonary arterial hypertension (PAH)-related symptoms and impact of PAH on daily life. The physical impact domain consists of walking slowly on a flat surface, walking quickly on a flat surface, walking uphill, carrying things, doing light indoor household chores, washing, or dressing oneself, and needing help from others. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (not difficult at all) to 4 (extremely difficult). A domain score was calculated by summing the individual responses for each item and dividing by the number of impact items (range: 0=no physical impact to 4=severe physical impact). A higher score indicated more severe physical impact. Mean change from baseline in responses in physical symptoms of the PAH-SYMPACT questionnaire at Week 24 is reported.

Time frame:
Baseline and Week 24
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in the Physical Impacts Domain Score of Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT)®
Scores on a scaleSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Mean Change From Baseline in the Physical Impacts Domain Score of Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT)®-0.0 ± 0.66-0.2 ± 0.65
SecondaryMean Change From Baseline in the Cardiopulmonary Symptoms Domain Score of PAH-SYMPACT®

The PAH SYMPACT is a 23-item questionnaire to measure PAH-related symptoms and impact of PAH on daily life. The cardiopulmonary symptoms consist of shortness of breath, fatigue, lack of energy, swelling in the ankles or legs, swelling in the stomach area, and cough. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (no symptom at all) to 4 (very severe symptoms). The mean individual symptom item score was determined for each of the 6 items and a domain score was calculated by summing the mean individual symptom item scores and dividing by the number of items (range: 0=no cardiopulmonary symptoms to 4=severe cardiopulmonary symptoms). A higher score indicated more severe symptoms experienced. Mean change from baseline in cardiopulmonary symptoms of the PAH-SYMPACT questionnaire at Week 24 is reported.

Time frame:
Baseline and Week 24
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in the Cardiopulmonary Symptoms Domain Score of PAH-SYMPACT®
Scores on a scaleSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Mean Change From Baseline in the Cardiopulmonary Symptoms Domain Score of PAH-SYMPACT®-0.1 ± 0.34-0.2 ± 0.31
SecondaryMean Change From Baseline in the Cognitive/Emotional Impacts Domain Score of PAH-SYMPACT®

The PAH SYMPACT is a 23-item questionnaire to measure PAH-related symptoms and impact of PAH on daily life. The Cognitive/Emotional Impact domain consists of thinking clearly, feeling sad, feeling worried, and feeling frustrated. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (not difficult at all) to 4 (extremely difficult). A domain score was calculated by summing the individual responses for each item and dividing by the number of impact items (range: 0=no cognitive/emotional impact to 4=severe cognitive/emotional impact). A higher score indicated more severe cognitive/emotional impact. Mean change from baseline in responses in the Cognitive/Emotional Impacts Domain Score of the PAH-SYMPACT questionnaire at Week 24 is reported.

Time frame:
Baseline and Week 24
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in the Cognitive/Emotional Impacts Domain Score of PAH-SYMPACT®
Scores on a scaleSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Mean Change From Baseline in the Cognitive/Emotional Impacts Domain Score of PAH-SYMPACT®-0.1 ± 0.69-0.0 ± 0.62
SecondaryPercentage of Participants Who Experience an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical investigation participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experienced an AE are presented.

Time frame:
Up to ~35 Months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experience an Adverse Event (AE)
Percentage of participantsSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Percentage of Participants Who Experience an Adverse Event (AE)89.490.0
SecondaryPercentage of Participants Who Discontinued Study Treatment Due to AEs

An AE is any untoward medical occurrence in a clinical investigation participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study treatment due to an AE are presented.

Time frame:
Up to ~35 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Treatment Due to AEs
Percentage of participantsSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Percentage of Participants Who Discontinued Study Treatment Due to AEs3.10.0
SecondaryNumber of Participants Who Had Anti-drug Antibodies (ADAs) to Sotatercept

Blood samples collected at designated timepoints were used to determine the ADA response to sotatercept. The number of participants who had ADAs to sotatercept over time is presented.

Time frame:
Up to ~35 Months
Reported as:
Count of participants · Participants
Number of Participants Who Had Anti-drug Antibodies (ADAs) to Sotatercept
ParticipantsSotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH Therapy
Number of Participants Who Had Anti-drug Antibodies (ADAs) to Sotatercept63—

Adverse events

Collected over Death and adverse events up to approximately 35 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotatercept10/161 (6.2%)39/160 (24.4%)127/160 (79.4%)
Placebo13/160 (8.1%)45/160 (28.1%)128/160 (80%)
Most frequent serious events
Showing 10 of 104
Most frequent serious events
EventSotaterceptPlacebo
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders0/1608/160
AnaemiaBlood and lymphatic system disorders5/1600/160
PneumoniaInfections and infestations4/1604/160
Cardiac failureCardiac disorders0/1603/160
Right ventricular failureCardiac disorders0/1603/160
Atrial fibrillationCardiac disorders1/1602/160
Atrial flutterCardiac disorders2/1600/160
Gastrointestinal haemorrhageGastrointestinal disorders2/1600/160
Rectal haemorrhageGastrointestinal disorders2/1600/160
Anal abscessInfections and infestations2/1600/160
Most frequent other events
Showing 10 of 30
Most frequent other events
EventSotaterceptPlacebo
EpistaxisRespiratory, thoracic and mediastinal disorders50/16011/160
TelangiectasiaSkin and subcutaneous tissue disorders42/16018/160
Oedema peripheralGeneral disorders15/16038/160
DyspnoeaRespiratory, thoracic and mediastinal disorders20/16031/160
DiarrhoeaGastrointestinal disorders24/16023/160
HeadacheNervous system disorders22/16024/160
FatigueGeneral disorders21/16015/160
NasopharyngitisInfections and infestations17/16021/160
NauseaGastrointestinal disorders14/16020/160
CoughRespiratory, thoracic and mediastinal disorders14/16020/160

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH TherapyTotal
Mean57.2 ± 15.455.0 ± 17.356.1 ± 16.4
Sex: Female, Male
Sex: Female, Male(Participants)Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH TherapyTotal
Female120112232
Male414889
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH TherapyTotal
Hispanic or Latino262551
Not Hispanic or Latino121125246
Unknown or Not Reported141024
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH TherapyTotal
American Indian or Alaska Native011
Asian6814
Native Hawaiian or Other Pacific Islander000
Black or African American145
White141136277
More than one race000
Unknown or Not Reported131124
PAH World Health Organization Functional Class (WHO FC) (Class II or III)
PAH World Health Organization Functional Class (WHO FC) (Class II or III)(Count of Participants)Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH TherapyTotal
WHO FC II363268
WHO FC III124128252
Background PAH therapy (double or triple therapy)
Background PAH therapy (double or triple therapy)(Count of Participants)Sotatercept Plus Background Pulmonary Arterial Hypertension (PAH) TherapyPlacebo Plus Background PAH TherapyTotal
Double116115231
Triple444589
08

Study locations

152 sites
  • Arizona Pulmonary Specialists ( Site 1010)
    Scottsdale, Arizona 85258, United States
  • University of Arizona ( Site 1006)
    Tucson, Arizona 85724, United States
  • University of California San Diego ( Site 1002)
    La Jolla, California 92037, United States
  • UCLA Medical Center ( Site 1068)
    Los Angeles, California 90095, United States
  • University of California Irvine ( Site 1086)
    Orange, California 92868, United States
  • Santa Barbara Pulmonary Associates ( Site 1060)
    Santa Barbara, California 93105-5316, United States
  • University of California Davis Medical Center ( Site 1064)
    Sherman Oaks, California 95817, United States
  • University of Colorado Hospital ( Site 1013)
    Aurora, Colorado 80045, United States
  • AdventHealth Medical Group Advanced Lung Disease ( Site 1058)
    Orlando, Florida 32804, United States
  • University of Iowa Hospital and Clinics ( Site 1050)
    Iowa City, Iowa 52242, United States
  • Johns Hopkins Hospital ( Site 1036)
    Baltimore, Maryland 21287-0005, United States
  • Tufts Medical Center - PPDS ( Site 1014)
    Boston, Massachusetts 02111-1526, United States
  • Boston Medical Center ( Site 1012)
    Boston, Massachusetts 02118, United States
  • University of Michigan ( Site 1011)
    Ann Arbor, Michigan 48109, United States
  • University of Kansas Medical Center ( Site 1020)
    Kansas City, Missouri 66160, United States
  • Washington University School of Medicine ( Site 1022)
    St Louis, Missouri 63110, United States
  • University of New Mexico, Health Sciences Center ( Site 1048)
    Albuquerque, New Mexico 87131, United States
  • NYU Langone Health ( Site 1052)
    New York, New York 10016-9196, United States
  • University of North Carolina at Chapel Hill ( Site 1042)
    Chapel Hill, North Carolina 27514, United States
  • The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001)
    Cincinnati, Ohio 45219, United States
  • University of Cincinnati ( Site 1035)
    Cincinnati, Ohio 45219, United States
  • The Cleveland Clinic Foundation Taussig Cancer Center ( Site 1065)
    Cleveland, Ohio 44195, United States
  • Nazih Zuhdi Transplantation Institute ( Site 1084)
    Oklahoma City, Oklahoma 73112-4421, United States
  • Oregon Health & Science University ( Site 1054)
    Portland, Oregon 97239, United States
  • Medical University of South Carolina ( Site 1003)
    Charleston, South Carolina 29425-8900, United States
  • Vanderbilt University Medical Center ( Site 1027)
    Nashville, Tennessee 37232, United States
  • University of Texas Southwestern Medical Center ( Site 1038)
    Dallas, Texas 78701, United States
  • University of Utah ( Site 1049)
    Salt Lake City, Utah 84132-0001, United States
  • Cardiologia Palermo ( Site 1911)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1425BNG, Argentina
  • Centro Medico Dra De Salvo ( Site 1904)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1426ABP, Argentina
  • Hospital Universitario Austral ( Site 1901)
    Pilar, Buenos Aires B1629ODT, Argentina
  • Instituto de Investigaciones Clinicas Quilmes ( Site 1903)
    Quilmes, Buenos Aires 1878, Argentina
  • Instituto De Enfermedades Respiratorias E Investigacion Medica ( Site 1910)
    Villa Vatteone, Buenos Aires B1853AIK, Argentina
  • Instituto Médico DAMIC ( Site 1909)
    Córdoba, Córdoba Province 5003DCE, Argentina
  • Instituto Medico Rio Cuarto ( Site 1907)
    Río Cuarto, Córdoba Province X5800AEV, Argentina
  • Hospital Provincial del Centenario ( Site 1912)
    Rosario, Santa Fe Province 2002, Argentina
  • Instituto Cardiovascular de Rosario ( Site 1906)
    Rosario, Santa Fe Province S2000DSR, Argentina
  • Sanatorio Parque ( Site 1905)
    Rosario, Santa Fe Province S2000DSV, Argentina
  • Sanatorio Allende ( Site 1908)
    Córdoba, X5021FPQ, Argentina
  • Hospital Provincial Dr. Jose M. Cullen ( Site 1902)
    Santa Fe, S3000EOZ, Argentina
  • Royal Prince Alfred Hospital ( Site 1106)
    Camperdown, New South Wales 2050, Australia
  • John Hunter Hospital ( Site 1101)
    Newcastle, New South Wales 2308, Australia
  • Prince Charles Hospital ( Site 1104)
    Chermside, Queensland 4032, Australia
  • Princess Alexandra Hospital ( Site 1108)
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital ( Site 1109)
    Adelaide, South Australia 5000, Australia
  • Royal Hobart Hospital ( Site 1107)
    Hobart, Tasmania 7000, Australia
  • Fiona Stanley Hospital ( Site 1103)
    Murdoch, Western Australia 6150, Australia
  • Medizinische Universitat Wien ( Site 2001)
    Vienna, State of Vienna 1090, Austria
  • Medizinische Universität Graz ( Site 2003)
    Graz, Styria 8036, Austria
  • Medizinische Universitat Innsbruck ( Site 2004)
    Innsbruck, Tyrol 6020, Austria
  • Ordensklinikum Linz GmbH Elisabethinen ( Site 2002)
    Linz, Upper Austria 4020, Austria
  • Hopital Erasme ( Site 1402)
    Anderlecht, Bruxelles-Capitale, Region de 1070, Belgium
  • UZ Gasthuisberg ( Site 1401)
    Leuven, Vlaams-Brabant 3000, Belgium
  • Hospital Madre Teresa ( Site 1804)
    Belo Horizonte, Minas Gerais 30430-142, Brazil
  • Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 1805)
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Hospital Sao Paulo ( Site 1806)
    São Paulo, São Paulo 04038-031, Brazil
  • Instituto do Coracao - HCFMUSP ( Site 1803)
    São Paulo, 05403-000, Brazil
  • University of Alberta Hospital ( Site 2101)
    Edmonton, Alberta T6G 2B7, Canada
  • St Boniface General Hospital ( Site 2106)
    Winnepeg, Manitoba R2H 2A6, Canada
  • McMaster University - HSC ( Site 2105)
    Hamilton, Ontario L8N 4A6, Canada
  • Sir Mortimer B Davis Jewish General Hospital ( Site 2103)
    Montreal, Quebec H3T 1E2, Canada
  • Centro Cardiovascular Colombiano Clínica Santa María Clínica Cardio VID ( Site 3402)
    Medellín, Antioquia 50034, Colombia
  • Fundacion Neumologica Colombiana ( Site 3403)
    Bogota, Cundinamarca 110131, Colombia
  • Fundacion Valle Del Lili ( Site 3401)
    Cali, Valle del Cauca Department 760032, Colombia
  • Centro Medico Imbanaco de Cali S.A ( Site 3404)
    Cali, Valle del Cauca Department 760042, Colombia
  • University Hospital Centre Split city ( Site 3901)
    Split, Split-Dalmatia County 21000, Croatia
  • Klinicki Bolnicki Centar Zagreb ( Site 3902)
    Zagreb, Zagreb County 10000, Croatia
  • Institut Klinicke a Experimentalni Mediciny ( Site 2202)
    Prague, Praha 4 140 21, Czechia
  • Vseobecna fakultni nemocnice v Praze ( Site 2201)
    Prague, 128 08, Czechia
  • Rigshospitalet ( Site 3802)
    København Ø, Capital Region 2100, Denmark
  • Aarhus Universitetshospital, Skejby ( Site 3801)
    Aarhus, Central Jutland 8200, Denmark
  • Hopital Louis Pasteur ( Site 1311)
    Nice, Alpes-Maritimes 06001, France
  • Hopital Louis Pradel ( Site 1317)
    Lyon, Auvergne 69003, France
  • Hopitaux Universitaires de Strasbourg ( Site 1307)
    Strasbourg, Bas-Rhin 67000, France
  • Hopital Cavale Blanche ( Site 1314)
    Brest, Brittany Region 29200, France
  • CHU Caen Normandie ( Site 1325)
    Caen, Calvados 14033, France
  • CHU de Besancon ( Site 1303)
    Besançon, Doubs 25000, France
  • Hopital Haut Leveque ( Site 1312)
    Bordeaux, Gironde 33604, France
  • CHU de Toulouse - Hopital Larrey ( Site 1315)
    Toulouse, Haute-Garonne 31059, France
  • C.H.U. de Tours - Hopital Bretonneau ( Site 1310)
    Tours, Indre-et-Loire 37000, France
  • Hopital Nord Laennec ( Site 1309)
    Nantes, Loire-Atlantique 44000, France
  • CHU Angers ( Site 1313)
    Angers, Maine-et-Loire 49933, France
  • C.H.U. de Nancy. Hopital de Brabois Adultes ( Site 1308)
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54500, France
  • Centre Hospitalier Universitaire de Saint-Etienne ( Site 1302)
    Saint-Priest-en-Jarez, Pays de la Loire Region 42270, France
  • CHU - Hopital de Bicetre ( Site 1304)
    Le Kremlin-Bicêtre, Val-de-Marne 94270, France
  • CHU de Poitiers ( Site 1316)
    Poitiers, Vienne 86000, France
  • Universitaetsklinikum Heidelberg ( Site 1509)
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Krankenhaus Neuwittelsbach ( Site 1510)
    Munich, Bavaria 80639, Germany
  • Universitaetsklinik Regensburg ( Site 1503)
    Regensburg, Bavaria 93053, Germany
  • Medizinische Hochschule Hannover ( Site 1505)
    Hanover, Lower Saxony 30625, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH ( Site 1512)
    Bad Oeynhausen, North Rhine-Westphalia 35392, Germany
  • Uniklinik Köln ( Site 1511)
    Cologne, North Rhine-Westphalia 50937, Germany
  • Universitatsklinikum des Saarlandes ( Site 1513)
    Homburg, Saarland 66421, Germany
  • Universitaetsklinikum Carl Gustav Carus ( Site 1501)
    Dresden, Saxony 01307, Germany
  • Universitatsklinikum Leipzig ( Site 1508)
    Leipzig, Saxony 04103, Germany
  • Universitaetsklinik und Poliklinik Halle/Saale ( Site 1502)
    Halle, Saxony-Anhalt 06120, Germany
  • DRK Kliniken Berlin Westend ( Site 1507)
    Berlin, 14050, Germany
  • Evangelismos General Hospital of Athens ( Site 3605)
    Athens, Attica 106 76, Greece
  • Onassis Cardiac Surgery Center ( Site 3602)
    Athens, Attica 176 74, Greece
  • Attikon University General Hospital of Athens ( Site 3604)
    Haidari, Attica 124 62, Greece

Showing the first 100 of 152 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Kopec G, Meyer G, Olsson KM, Fu W, Shi Y, Miller B, Kim SS, Mackenzie HS, Brambatti M, Patel MJ, Koglin J, Cornell AG, Humbert M; HYPERION Trial Investigators. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. N Engl J Med. 2025 Oct 23;393(16):1599-1611. doi: 10.1056/NEJMoa2508170. Epub 2025 Sep 30. PubMed 41025556 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Apr 2025, 36 months.

Results were first posted in Apr 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2021
First posted
Mar 23, 2021
StartActual
Mar 18, 2022
Primary completionActual
Apr 3, 2025
CompletionActual
Apr 3, 2025
Results first posted
Apr 27, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04811092
Responsible party
Sponsor
First posted
Mar 23, 2021
Start date
Mar 18, 2022
Primary completion
Apr 3, 2025
Completion
Apr 3, 2025
Results posted
Apr 27, 2026
Last update
Jun 8, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion